Login to Your Account



Another bend in the road for Prosensa suggests new path for drisapersen

By Marie Powers
Staff Writer

Tuesday, June 3, 2014

In a move that could potentially signal greater flexibility by regulators in reviewing groundbreaking drugs with new mechanisms of action in rare diseases with clear unmet medical need, the FDA provided guidance for a potential regulatory path, under accelerated approval, for drisapersen.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription